TR201901826T4 - Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler. - Google Patents
Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler. Download PDFInfo
- Publication number
- TR201901826T4 TR201901826T4 TR2019/01826T TR201901826T TR201901826T4 TR 201901826 T4 TR201901826 T4 TR 201901826T4 TR 2019/01826 T TR2019/01826 T TR 2019/01826T TR 201901826 T TR201901826 T TR 201901826T TR 201901826 T4 TR201901826 T4 TR 201901826T4
- Authority
- TR
- Turkey
- Prior art keywords
- binding
- preventing
- methods
- respective receptors
- inhibiting
- Prior art date
Links
- 108090000978 Interleukin-4 Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 230000029069 type 2 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Mevcut tarifname, IL-4 ve/veya IL-13'ün ilgili reseptörlerine bağlanmasını önleyen bir protein içeren bir bileşimin terapötik olarak etkili miktarıın ihtiyacı olan bir sujeye tatbik edilmesini içeren bir rahatsızlığın tedavi edilmesi, iyileştirilmesi ya da önlenmesi için yöntemler ile ilgilidir. Bazı uygulamalarda, rahatsızlık tercihen Th2 immün yanıtının bir artışı ile ilişkilidir. Bazı uygulamalarda, alerjik astımı, riniti, konjunktiviti, akciğer fibrozunu, sistik fibrozu, kronik obstruktif pulmoner hastalığı, pulmoner alveolar proteinozu ya da yetişkin solunum zorluğu sendromunu tedavi etmek için tatbik tercihen lokal olarak akciğere yapılır.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570018P | 2011-12-13 | 2011-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201901826T4 true TR201901826T4 (tr) | 2019-03-21 |
Family
ID=47552959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/01826T TR201901826T4 (tr) | 2011-12-13 | 2012-12-12 | Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler. |
Country Status (13)
Country | Link |
---|---|
US (6) | US9572863B2 (tr) |
EP (3) | EP3842058B1 (tr) |
JP (5) | JP6163162B2 (tr) |
CN (2) | CN109432402B (tr) |
AU (1) | AU2012350660B2 (tr) |
CA (1) | CA2858962C (tr) |
DK (2) | DK2790719T3 (tr) |
ES (2) | ES2863410T3 (tr) |
HU (2) | HUE042720T2 (tr) |
PL (2) | PL3453400T3 (tr) |
SG (2) | SG10201604566QA (tr) |
TR (1) | TR201901826T4 (tr) |
WO (1) | WO2013087660A1 (tr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS58839B1 (sr) * | 2010-06-08 | 2019-07-31 | Pieris Pharmaceuticals Gmbh | Muteini lipokalina u suzama koji vezuju il-4 r alfa |
HUE042720T2 (hu) | 2011-12-13 | 2019-07-29 | Pieris Pharmaceuticals Gmbh | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
EP3145945B1 (en) * | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
US10501510B2 (en) | 2015-07-15 | 2019-12-10 | Pieris Pharmaceuticals Gmbh | Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof |
CN107474134B (zh) * | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
WO2018134274A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
MX2019012570A (es) | 2017-04-21 | 2019-12-02 | Kindred Biosciences Inc | Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario. |
CN111514292B (zh) * | 2018-12-25 | 2023-06-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
CN113613669A (zh) * | 2019-03-29 | 2021-11-05 | 阿斯利康有限公司 | 用于治疗哮喘的脂质运载蛋白突变蛋白 |
EP3946417A1 (en) | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
PE20240799A1 (es) | 2020-12-18 | 2024-04-18 | Astrazeneca Ab | Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma |
CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
SI1087778T1 (sl) | 1998-06-08 | 2006-02-28 | Hoffmann La Roche | Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c |
US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
WO2003099207A2 (en) * | 2002-05-24 | 2003-12-04 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
WO2007107563A2 (en) | 2006-03-20 | 2007-09-27 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
DK2046820T3 (da) * | 2006-08-01 | 2011-02-07 | Pieris Ag | Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf |
AU2008274938A1 (en) * | 2007-07-11 | 2009-01-15 | Aerovance, Inc. | Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation |
RS58839B1 (sr) | 2010-06-08 | 2019-07-31 | Pieris Pharmaceuticals Gmbh | Muteini lipokalina u suzama koji vezuju il-4 r alfa |
HUE042720T2 (hu) | 2011-12-13 | 2019-07-29 | Pieris Pharmaceuticals Gmbh | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
-
2012
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja active Active
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en active Active
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en active Application Filing
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh active Active
- 2012-12-12 US US14/364,449 patent/US9572863B2/en active Active
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh active Active
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja active Active
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja active Active
- 2019-07-16 US US16/513,636 patent/US10857202B2/en active Active
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201901826T4 (tr) | Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler. | |
NZ592839A (en) | Treatment of diseases, disorders or conditions of the lung using placental cells | |
RU2015144185A (ru) | Лечение заболеваний, опосредованных тh2, путем ингибирования бромодоменов | |
CA2897464C (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
BR112015012312A2 (pt) | método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito | |
WO2010120511A3 (en) | Method of treating respiratory disorders | |
WO2007082068A3 (en) | Methods and compositions for treating asthma in human and non human primates | |
EA201590933A1 (ru) | Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования | |
EP2120935A4 (en) | NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA | |
WO2011160086A3 (en) | Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system | |
EA201201393A1 (ru) | Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка | |
EA201201392A1 (ru) | Кнопочное устройство мундштука ингалятора сухого порошка | |
JP2014520854A5 (tr) | ||
MX2010008685A (es) | Farmacoforos duales-antagonistas muscarinicos de pde4. | |
EA201201389A1 (ru) | Ингалятор, создающий турбулентность | |
EP2125728A4 (en) | NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA | |
BR112022020403A2 (pt) | Composições e métodos para tratar complicações de infecções virais e outros transtornos repiratórios | |
Kühn et al. | Impact of dose and dosing frequency of intranasal AZD8848 (a TLR7 agonist) on biomarker response in healthy volunteers | |
Gauvreau et al. | A Randomized, Double-Blind, Placebo Controlled Multicenter Study To Evaluate the Efficacy of a Humanized Interleukin-9 Monoclonal Antibody (MEDI-528) on the Late Asthmatic Response in Adults with Atopic Asthma. | |
Danielsson et al. | Antagonism of the Tmem16a calcium-activated chloride channel attenuates allergic lung inflammation | |
Danielsson et al. | C35 ASTHMA AND ALLERGY CELLULAR INVESTIGATIONS: Antagonism Of The Tmem16a Calcium-Activated Chloride Channel Attenuates Allergic Lung Inflammation | |
Syrkina et al. | TLR 4 and JNK I Link to Smoke Inhalation Lung Injury from Fire. | |
Hoymann et al. | Carbon black particles facilitate allergic sensitization and enhance airway hyperresponsiveness in a mouse model of allergic asthma | |
Sorkness et al. | Altered Pulmonary Expression Of Sonic Hedgehog Signaling Pathway Genes During Abnormal Peripheral Airway Branching Morphogenesis After Viral Bronchiolitis In Young Rats | |
Forsman-Semb et al. | Sputum MUC5AC as a Biomarker for Mucus Hypersecretion in COPD Patients. |